Consensus for 2024 revenue is $198.33M. Narrows 2024 cash guidance to $370M-$390M from $360M-$390M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on VNDA: Vanda Pharmaceuticals reports Q3 EPS (9c), consensus (16c) Wingstop upgraded, Estee Lauder downgraded: Wall Street’s top analyst calls Vanda Pharmaceuticals initiated with a Buy at H.C. Wainwright Is VNDA a Buy, Before Earnings? Biotech Alert: Searches spiking for these stocks today Disclaimer & DisclosureReport an Issue
